Pharmidex joins London Mayor Boris Johnson's trade mission to US
January 6, 2015

Boris Johnson is heading to the United States on a six-day trade mission aimed at bolstering London's science and technology industries.

Mr Boris Johnson’s US Trade Mission


Mr Boris Johnson, the Mayor of London has recently been in the US trying to attract investment for British businesses. Mr Johnson is using the US trade mission to promote London's TechCity - which supports the cluster of technology firms based in east London - and MedCity, which was launched last year to support life sciences.


He looked to visit Harvard University’s Stem Cell Institute (HSCI) in an attempt to bring together collaborations between London and Boston life sciences. Mr Johnson said “'The United States is a hugely important trading partner for London, offering massive opportunities for investment in this country and for businesses wanting to expand internationally. I want London to capitalise on the great relationships we have in Boston, New York City and Washington DC”.


In Boston and New York, the Mayor was joined by senior business figures from London's tech and life science sectors including Dr Mo Alavijeh of Pharmidex.


For more information please see: http://www.bbc.co.uk/news/uk-england-london-31161270


November 5, 2025
We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜
November 4, 2025
We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.
November 3, 2025
We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.
More Posts